Williams 1993.

Methods	Six‐week randomised, double‐blind multicentre study
Participants	In‐ and outpatients fulfilling DSM‐III criteria for major depressive episode, with a score of at least 17 on the Hamilton Rating Scale for Depression‐21 item (HDRS‐21). Age range: 20‐86 years Exclusion criteria: suicide risk, other psychiatric disorder, alcohol abuse, use of MAOI in the previous 2 weeks, use of other antidepressants in the previous week, pregnancy, lactation, known allergy to trial medication.
Interventions	Fluoxetine: 60 participants Moclobemide: 62 participants Fluoxetine dose range: 20‐40 mg/day Moclobemide dose range: 300‐600 mg/day
Outcomes	Primary outcome: HDRS‐21 Secondary outcome: Clinical Global Impression (CGI)
Notes	Funding: unclear
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double blind, no further information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Number and reasons for dropout reported, but not included in the analysis
Selective reporting (reporting bias)	Unclear risk	Only most common side effects were reported. Mean endpoint scores not reported
Other bias	Unclear risk	Funding: unclear